Vanda Pharmaceuticals Inc. (VNDA) on Focus After Raising In Today’s Session

September 17, 2017 - By Linda Rogers

Investors sentiment decreased to 1.29 in Q4 2016. Its down 1.10, from 2.39 in 2016Q3. It is negative, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 46 reduced holdings. 20 funds opened positions while 55 raised stakes. 39.66 million shares or 1.45% less from 40.25 million shares in 2016Q3 were reported.
North Star Inv Management Corp, a Illinois-based fund reported 5,000 shares. 70,961 are held by Federated Investors Pa. Nationwide Fund Advisors holds 0% or 39,637 shares in its portfolio. Grp holds 21,072 shares or 0% of its portfolio. Pnc Svcs Gru Inc accumulated 0.01% or 282,292 shares. First Mercantile Tru Company reported 0.02% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Systematic Management Limited Partnership owns 119,380 shares for 0.03% of their portfolio. One Trading L P reported 6,255 shares stake. Kingdon Mngmt Lc has 418,732 shares for 0.32% of their portfolio. Panagora Asset Management invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Millennium Management Llc holds 0.03% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 1.02M shares. Tiaa Cref Invest Mgmt Ltd Com reported 389,278 shares. Blackrock Institutional Tru Na, a California-based fund reported 1.22 million shares. Acadian Asset Mngmt Ltd Liability Corporation invested in 1.37M shares. Magee Thomson Prtnrs Ltd accumulated 75 shares.

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 4.25% or $0.75 on September 15, reaching $18.4. About 2.04 million shares traded or 240.41% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since September 17, 2016 and is uptrending. It has outperformed by 34.90% the S&P500.
The move comes after 8 months positive chart setup for the $825.39 million company. It was reported on Sep, 17 by Barchart.com. We have $20.06 PT which if reached, will make NASDAQ:VNDA worth $74.29 million more.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on November, 1. They expect $-0.10 EPS, down 266.67 % or $0.16 from last year’s $0.06 per share. After $-0.03 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 233.33 % negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 16 analyst reports since September 2, 2015 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Tuesday, June 27. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, October 21 by Brean Capital. The company was maintained on Monday, June 26 by Jefferies. The stock has “Market Outperform” rating by JMP Securities on Friday, August 26. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, August 3. The company was maintained on Thursday, August 3 by Oppenheimer. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The company was maintained on Monday, September 4 by Jefferies. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies on Thursday, October 6. The rating was initiated by Aegis Capital on Wednesday, November 9 with “Buy”.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Marketwatch.com which released: “Vanda Pharma shares decline as goal of itch drug study not reached” on September 13, 2017, also Seekingalpha.com with their article: “Vanda Pharmaceuticals: An Early Stage Bioscience Consideration” published on July 26, 2017, Seekingalpha.com published: “Vanda Pharmaceuticals Keeps Chugging Along” on June 26, 2017. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Prnewswire.com and their article: “Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech …” published on September 06, 2017 as well as Zacks.com‘s news article titled: “Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA …” with publication date: August 29, 2017.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has market cap of $825.39 million. The Firm is focused on the development and commercialization of therapies to address unmet medical needs. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ , Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.